In clinical research, earlier GLP-1s were associated with about 3-5% body-weight reduction over six to twelve months, while newer options like semaglutide and tirzepatide average closer to 12-18% weight loss over a year
The discovery of the presence of a GLP-1 receptor on other tissues and its participation in appetite regulation, gastric emptying, the pancreas, and glucose metabolism, the research interest in the use of GLP-1 receptor agonists has been extensive
Another study, said to represent the largest dataset to date assessing pancreatic risk in GLP-1 RA and SGLT2 users in adults with T2D and obesity, compared a cohort of 77,665 patients treated with GLP-1 RAs at centers in the Mayo Clinic Platform with 35,435 patients treated with SGLT2 inhibitors
Semaglutide: A review of its pharmacology and clinical applications in diabetes and obesity
Call the number above to learn more